Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 3, 1999, Pages 133-143

  Pelot, Michele R ^a   Pearson, Denise A ^a   Swenson, Kirsten ^a   Zhao, Guiling ^a   Sachs, Jessica ^a   Yang, Yong Guang ^a   Sykes, Megan ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Donor leukocyte infusion; Graft vs. host disease; Mixed chimerism

Indexed keywords

CYCLOPHOSPHAMIDE;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CHIMERA; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; METABOLISM; METHODOLOGY; MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; CHIMERA; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HEMATOPOIESIS; INFUSIONS, INTRAVENOUS; LEUKOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032617123     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1999.v5.pm10392959     Document Type: Article

References (47)

1. O'Reilly RJ, Collins NH, Kernan N, et al: Transplantation of marrow depleted of T cells by soybean lectin agglutination and E-rosette depletion: major histocompatibility complex-related graft resistance in leukemic transplant recipients. Transplant Proc 17:455, 1985.
2. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlace PB, Messner HA, Rimm AA, Rozmann C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988.
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990.
4. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED: Antileukemic effect of chronic graft-versus-host disease. N Engl J Med 304:1529, 1981.
5. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, FeferA, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheerer MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720, 1989.
6. Martin PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 178:703, 1993.
7. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307:168, 1984.
8. Sharabi Y, Sachs DH: Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 169:493, 1989.
9. Tomita Y, Khan A, Sykes M: Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a non-myeloablative regimen. J Immunol 153:1087, 1994.
10. Tomita Y, Khan A, Sykes M: Mechanism by which additional monoclonal antibody injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 61:477, 1996.
11. Sykes M, Sheard MA, Sachs DH: Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 168:2391, 1988.
12. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980.
13. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J Immunol 131:2445, 1983.
14. Sykes M, Sheard M, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol 141:2282, 1988.
15. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979.
16. Tomita Y, Sachs DH, Khan A, Sykes M: Additional mAb injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 61:469, 1996.
17. Ozato K, Mayer NM, Sachs DH: Monoclonal antibodies to mouse major histocompatibility complex antigens IV. A series of hybridoma clones producing anti-H-2d antibodies and an examination of expression of H-2d antigens on the surface of these cells. Transplantation. 34:113, 1982.
18. Ozato K, Henkart P, Jensen C, Sachs DH: Spatially distinct allodeterminants of the H-2Kk molecule as detected by monoclonal anti-H-2 antibodies. J Immunol 126:1780, 1981.
19. Sherman LA, Randolph CP: Monoclonal anti-H-2Kb antibodies detect serological differences between H-2Kb mutants. Immunogenetics 12:183, 1981.
20. Lee LA, Sergio JJ, Sykes M: Natural killer cells weakly resist engraftment of allogeneic long-term multilineage-repopulating hematopoietic stem cells. Transplantation 61:125, 1996.
21. Down JD, Ploemacher RE: Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol 21:913, 1993.
22. Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y: Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 73:2025, 1989.
23. Kondo M, Weissman IL, Akashi K: Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91:661, 1998.
24. Sykes M, Harty MW, Pearson DA: Strain dependence of IL-2-induced GVHD protection: Evidence that IL-2 inhibits selected CD4 functions. J Immunother 15:11, 1994.
25. Sykes M, Harty MW, Szot GL, Pearson DA: Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4-and CD8-mediated graft-versus-leukemia effects. Blood 83:2560, 1994.
26. Sykes M, Romick ML, Sachs DH: Interleukin 2 prevents graft-vs-host disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A 87:5633, 1990.
27. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA: CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 159:3460, 1997.
28. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329, 1993.
29. Sykes M, Chester CH, Sachs DH: Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow. Transplantation 46:327, 1988.
30. Xun CQ, Tsuchida M, Thompson JS: Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 64:297, 1997.
31. Antin JH, Ferrara JLM: Cytokine dysregulation in acute graft-versus-host disease. Blood 80:2964, 1992.
32. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360, 1994.
33. Antin JH: Graft-versus-leukemia: no longer an epiphenomenon. Blood 82:2273, 1993.
34. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederweiser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995.
35. Kolb HJ, Mittermuller J, Clemm Ch, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990.
36. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH: Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2-B10). J Immunol 136:28, 1986.
37. Sykes M, Eisenthal A, Sachs DH: Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J Immunol 140:2903, 1988.
38. Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dablberg S, Ramberg R, Thomas ED: Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of graft-versus-host disease. Blood 67:811, 1986.
39. Mackinnon S, Barnett L, Bourbis JH, Black P, Heller G, O'Reilly RJ: Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 80:3235, 1992.
40. Mangioni S, Balduzzi A, Rivolta A, Rovelli A, Nesi F, Rossi V, Busca A, Uderzo C, Miniero R, Biondi A: Long-term persistence of hematopoietic chimerism following sex-mismatched bone marrow transplantation. Bone Marrow Transplant 20:969, 1997.
41. Spitzer TR, McAfee SL, Sackstein R, Toh HC, Saidman S, Weymouth D, Preffer F, Colby C, Sachs DH, Sykes M: Induction of mixed chimerism and potent anti-tumor responses following nonmyeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation (BMT) for refractory hematologic malignancies. Blood 92(10s): 519a, 1998. [abstract]
42. Sykes M, Preffer F, McAffee S, Saidman SL, Colby C, Sackstein R, Sachs DH, Spitzer TR: Mixed lymphohematopoietic chimerism and graft-vs-lymphoma effects are achievable in adult humans following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 353:1255, 1999.
43. Sykes M, Saidman SL, Preffer F, McAfee S, Weymouth D, Dombkowski D, Andrews D, Colby C, Sackstein R, Sachs DH, Spitzer TR: Mixed lymphohematopoietic chimerism in adult recipients following non-myeloablative therapy and HLA-matched or mismatched donor bone marrow transplantation, and the effect of donor leukocyte infusions. Blood 92(10s): 520a, 1998. [abstract]
44. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mebra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531, 1997.
45. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756, 1998.
46. Giralt, S, Gajewski, J, Khouri, I, Korbling, M, Claxton, D, Mehra, R, Przepiorka, D, Andersson, B, Talpaz, M, Kantarjian, H, Champlin, R: Induction of graft-vs-leukemia (GVL) as primary treatment of chronic myelogenous leukemia. Blood 90 (Suppl 1): 418a. 1997. [abstract]
47. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA: The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol Rev 88:107, 1985.